WEST ALERT: Bragar Eagel & Squire, P.C. is Investigating West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
1. WST faces investigation over potential Board of Directors' fiduciary breach. 2. Class action claims West misled stakeholders about customer demand insights. 3. SmartDose device operations create significant margin pressure for WST. 4. WST's stock plummeted 38% following weak revenue and earnings forecasts. 5. Disclosures about client losses impact future revenue growth expectations.